恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

血清il-ag捕鱼平台

文字: 2018-7-19    浏览次数:813    


abstract 

while surgical resection represents the standard potentially curative therapy for liver cancer, transarterial chemoembolization (tace) has evolved as a standard therapy for intermediate-stage hepatocellular carcinoma (hcc) as well as liver metastases. however, it is still not fully understood which patients particularly benefit from tace. cytokines represent a broad category of signaling molecules that might reflect concomitant inflammation as an adverse prognostic factor. here, we evaluated the role of interleukin (il)-6, il-8, andcc-chemokine ligand (ccl)22 as biomarkers in the context of tace treatment.cytokine serum levels were analyzed by multiplex immunoassay in 54 patients(hcc: n = 44, liver metastases: n = 10)undergoing tace as well as 51 healthy controls. patients with primary and secondary liver cancer showed significantly elevated levels of il-6 and il-8 but not ccl22 compared to healthy controls. interestingly, low pre-interventional levels of il-6 and il-8 were predictors for an objective response after tace in binary logistic regression. in contrast, patients with high pre-interventional il-6 and il-8 serum levels not only poorly responded to tace but had a significantly impaired overall survival. serum levels of il-6 and il-8 represent promising biomarkers for patients undergoing tace and might help to pre-interventionally identify patients who particularly benefit from tace regarding objective treatment response and overall survival.

 

摘要:

目前,手术切除是肝癌根治性治疗的标准方案,tace是中期肝细胞癌(hcc)及肝转移癌的标准治疗方案。但是,目前尚无法完全理解为什么部分患者从tace治疗获益更多。细胞因子代表了一大类信号分子,可反应伴随炎症情况,从而作为不良预后因子。我们评估了白介素(il-6il-8cc-趋化因子配体(ccl22作为tace治疗生物标志物的作用。54名接受tace治疗的患者(hcc44人;肝转移:10人)和51名健康人对照接受了细胞因子血清水平测定(多重免疫测定)。原发和继发肝癌的患者il-6il-8水平显著提高,但ccl22与健康人类似。有趣的是,介入前低il-6,il-8水平是tace治疗客观缓解情况的预测因子(二元logistic回归分析)。相对的,介入前高il-6,il-8水平不仅治疗应答情况较差,而且os获益显著下降。血清il-6,il-8水平作为tace治疗的生物标志物值得期待,并可能有助于在介入治疗前确定从tace中获更多的患者,特别是客观治疗应答和总生存期。